NET LOSS PER SHARE

3 Months Ended

Mar. 31, 2025

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the three months ended March 31 (in thousands, except for per share amounts):


	Three Months Ended March 31,
	2025		2024
Loss from continuing operations, net noncontrolling interests and accrued preferred stock dividends	$	(15,465)	$	(18,653)
Loss from discontinued operations	(9,410)		(9,865)
Net loss attributable to NeueHealth, Inc. common shareholders	$	(24,875)	$	(28,518)
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted	8,570		8,079
Basic and diluted loss per share attributable to NeueHealth, Inc. common shareholders
Continuing operations	$	(1.80)	$	(2.31)
Discontinued operations	$	(1.10)	$	(1.22)
Net loss per share attributable to common stockholders, basic and diluted	$	(2.90)	$	(3.53)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive effect for the three months ended March 31 (in thousands):


	Three Months Ended March 31,
	2025	2024
Redeemable convertible preferred stock (as converted to common stock)	5,563	4,867
Issued and outstanding common stock warrants	1,834	1,834
Stock options to purchase common stock	422	614
Restricted stock units	2,261	575
Total	10,080	7,890